Here, we identified two ABC-DLBCL cell lines, U-2932 and RIVA, with primary resistance to CD37-targeting 177Lu-lilotomab satetraxetan treatment, derived from DE ABC-DLBCL with inactive TP53. This evidence concerns the gene CD37 and aneurysmal bone cyst.